INO - Inovio Pharmaceuticals - A NYSE Small-Cap Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : INO - Inovio Pharmaceuticals - A NYSE Small-Cap

INO 2.250

+4.7%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Lynn	9/17/2018 12:34:47 PM
	of 67

Inovio develops H3N2 Influenza DNA vaccine Sep. 17, 2018 9:17 AM ET By: Mamta Mayani, SA News Editor Inovio Pharmaceuticals (NYSEMKT: INO) announces that its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a preclinical study. Study results were published in the journal, Human Gene Therapy, in an article entitled, “A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza-A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.” This work was supported by a grant from the U.S. National Institutes of Health. Inovio is currently in discussions with third-party funders to support further development of the company’s technology with its advantages in promoting global human health. seekingalpha.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next